Under the agreement Bayer will further develop and commercialize ISIS-FXIRx in areas of high unmet medical need.
|Searching for more deal information? Current Partnering offers the following options:|
As part of the clinical development program, Bayer plans to evaluate the therapeutic profile of ISIS-FXIRx in an appropriate patient community.
Isis is eligible to receive near-term payments, including an up-front payment and payment upon advancement of the program following a Phase II study in patients with compromised kidney function.
Isis is also eligible to receive milestone payments as the drug advances toward the market.
In addition, Isis is eligible to receive tiered royalties on gross margins of ISIS-FXIRx.
After completion of ongoing activities at Isis, Bayer will assume all global clinical development as well as worldwide regulatory and commercialization responsibilities for ISIS-FXIRx.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2015
View: Top biotech companies